Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

GLS - Gelesis Holdings Inc


Previous close
0.1586
0   0%

Share volume: 185,167
Last Updated: Mon 10 Apr 2023 06:00:00 AM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 0.21%

PREVIOUS CLOSE
CHG
CHG%

$0.16
0.00
0.00%
This ticker is disabled and data are no longer maintained and up to date.
Fundamental analysis
4%
Profitability 0%
Dept financing 0%
Liquidity 0%
Performance 10%
Performance
5 Days
-3.35%
1 Month
-33.92%
3 Months
-62.24%
6 Months
-85.31%
1 Year
-97.13%
2 Year
-97.34%
Key data
Stock price
$0.16
P/E Ratio 
0.00
DAY RANGE
$0.14 - $0.16
EPS 
$0.00
52 WEEK RANGE
$0.11 - $5.67
52 WEEK CHANGE
-$0.97
MARKET CAP 
11.631 M
YIELD 
N/A
SHARES OUTSTANDING 
73.333 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
1.47
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$296,448
AVERAGE 30 VOLUME 
$789,016
Company detail
CEO: Yishai Zohar
Region: US
Website: www.gelesis.com
Employees: 103
IPO year: -
Issue type: Common Stock
Market: NYSE
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

Gelesis is a consumer-centered biotherapeutics company advancing a novel category of treatments for weight management and gut related chronic diseases. Its non-systemic superabsorbent hydrogels are the first and only made entirely from naturally derived building blocks, and they are inspired by the composition (i.e., water & cellulose) and mechanical properties (e.g., elasticity or firmness) of raw vegetables. They are conveniently administered in capsules to create a much larger volume of small, non-aggregating hydrogel pieces that become an integrated part of the meals, and act locally in the digestive system. Its portfolio includes Plenity®, an FDA-cleared product to aid in weight management, as well as potential therapies in development for patients with Type 2 Diabetes, Non-alcoholic Fatty Liver Disease (NAFLD)/Non-alcoholic Steatohepatitis (NASH), and Functional Constipation.

Recent news